NCT03430479: Anti PD-1 Antibody With Radiation Therapy in Patients With HER2-negative Metastatic Breast Cancer

NCT03430479
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Endocrine (Hormone) Therapy, Radiation Therapy

Key Eligibility Criteria:

Gender: Female
Age: 20 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Active or untreated central nervous system metastasis
https://ClinicalTrials.gov/show/NCT03430479

Comments are closed.

Up ↑